Literature DB >> 12682275

T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?

Christine M Posavad1, Anna Wald, Nancy Hosken, Meei Li Huang, David M Koelle, Rhoda L Ashley, Lawrence Corey.   

Abstract

During the course of investigating T cell responses to HSV among volunteers entering trials of investigational genital herpes vaccines, 6 of the 24 immunocompetent subjects with no prior history of oral/labial or genital herpes possessed HSV-specific T cell immunity but, by multiple determinants of even the most sensitive serological assays, remained seronegative to HSV-1 and -2. Of these six immune seronegative (IS; HSV-seronegative with HSV-specific T cell responses) subjects, two had transient HSV-specific T cell responses, while four had CD4(+) and CD8(+) T cell responses directed at HSV that persisted for up to 4 years. CD4(+) T cell clones were isolated that recognized and had high binding affinities to epitopes in HSV-2 tegument proteins. All six IS subjects had potential sexual exposure to an HSV-2-infected sexual partner. Oral and genital mucosal secretions were sampled and tested for the presence of infectious HSV and HSV DNA. No evidence of HSV was detected in >1500 samples obtained from these IS subjects. The identification of persistent T cell responses to HSV in seronegative subjects is a novel finding in the herpesvirus field and suggests either undetected infection or acquired immunity in the absence of infection. Understanding the basis of these acquired immune responses may be critical in developing effective vaccines for genital herpes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682275     DOI: 10.4049/jimmunol.170.8.4380

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

4.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

5.  Diversity in the acute CD8 T cell response to vaccinia virus in humans.

Authors:  Lichen Jing; Tiana M Chong; Christopher L McClurkan; Jay Huang; Brian T Story; David M Koelle
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

6.  Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.

Authors:  Christine M Posavad; Amalia S Magaret; Lin Zhao; Dawn E Mueller; Anna Wald; Lawrence Corey
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

7.  Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.

Authors:  Lichen Jing; Jürgen Haas; Tiana M Chong; Joseph J Bruckner; Greg C Dann; Lichun Dong; Joshua O Marshak; Christopher L McClurkan; Tori N Yamamoto; Susanne M Bailer; Kerry J Laing; Anna Wald; Georges M G M Verjans; David M Koelle
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 8.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

9.  Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Authors:  Ashok Cattamanchi; Christine M Posavad; Anna Wald; Yaela Baine; Jennifer Moses; Terry J Higgins; Richard Ginsberg; Richard Ciccarelli; Lawrence Corey; David M Koelle
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

10.  Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Authors:  Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Curr Trends Immunol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.